Abbonarsi

Behavioral Nudges as Patient Decision Support for Medication Adherence: The ENCOURAGE Randomized Controlled Trial - 31/12/21

Doi : 10.1016/j.ahj.2021.11.001 
Benjamin D. Horne *, , , Joseph B. Muhlestein *, , Donald L. Lappé *, , Heidi T. May *, Viet T. Le *, §, Tami L. Bair *, Daniel Babcock *, Daniel Bride *, Kirk U. Knowlton *, , Jeffrey L. Anderson *,
 Intermountain Medical Center Heart Institute, Salt Lake City, Utah, USA 
 Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, California, USA 
 Cardiology Division, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA 
§ Rocky Mountain University of Health Professions, Provo, Utah, USA 
 Division of Cardiovascular Medicine, Department of Medicine, University of California San Diego, La Jolla, California, USA 

1Address correspondence and reprint Benjamin D. Horne, Intermountain Medical Center Heart Institute, 5121 S. Cottonwood St., Salt Lake City, UT 84107, USA.Intermountain Medical Center Heart Institute5121 S. Cottonwood St.Salt Lake CityUT84107,USA

Riassunto

Background

Medication adherence is generally low and challenging to address because patient actions control healthcare delivery outside of medical environments. Behavioral nudging changes clinician behavior, but nudging patient decision-making requires further testing. This trial evaluated whether behavioral nudges can increase statin adherence, measured as the proportion of days covered (PDC).

Methods

In a 12-month parallel-group, unblinded, randomized controlled trial, adult patients in Intermountain Healthcare cardiology clinics were enrolled. Inclusion required an indication for statins and membership in SelectHealth insurance. Subjects were randomized 1:1 to control or nudges. Nudge content, timing, frequency, and delivery route were personalized by CareCentra using machine learning of subject motivations and abilities from psychographic assessment, demographics, social determinants, and the Intermountain Mortality Risk Score. PDC calculation used SelectHealth claims data.

Results

Among 182 subjects, age averaged 63.2±8.5 years, 25.8% were female, baseline LDL-C was 82.5±32.7 mg/dL, and 93.4% had coronary disease. Characteristics were balanced between nudge (n = 89) and control arms (n = 93). The statin PDC was greater at 12 months in the nudge group (PDC: 0.742±0.318) compared to controls (PDC: 0.639±0.358, P = 0.042). Adherent subjects (PDC ≥80%) were more concentrated in the nudge group (66.3% vs controls: 50.5%, P = 0.036) while a composite of death, myocardial infarction, stroke, and revascularization was non-significant (nudges: 6.7% vs control: 10.8%, P = 0.44).

Conclusions

Persuasive behavioral nudges driven by artificial intelligence resulted in a clinically important increase in statin adherence in general cardiology patients. This precision patient decision support utilized computerized nudge design and delivery with minimal on-going human input.

Il testo completo di questo articolo è disponibile in PDF.

Graphical Abstract




Image, graphical abstract

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Conflict of interest: BDH, HTM, and JLA are inventors of clinical decision tools that are licensed to CareCentra and Alluceo. BDH is the PI of grants involving clinical decision tools that were funded by Intermountain Healthcare’s Foundry innovation program, the Intermountain Research and Medical Foundation, CareCentra, GlaxoSmithKline, and AstraZeneca. BDH is a member of the scientific advisory board of Labme.ai. KUK is PI of and BDH a co-investigator of a grant funded by the Patient-Centered Outcomes Research Institute (PCORI). The other authors declare that they have no competing interests (JBM, DLL, VTL, TLB, D Babcock, and D Bride).
 Funding: This study was funded by a grant from the Intermountain Research and Medical Foundation (award 752, PI: BDH), an in-kind donation from CareCentra, and internal departmental funds. The funding sources had no role in the design of the study, the data analysis, the interpretation of the findings, or the writing or publication of the study manuscript.


© 2021  The Author(s). Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 244

P. 125-134 - Febbraio 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Association between economic and arrhythmic burden of paroxysmal atrial fibrillation in patients with cardiac implanted electronic devices
  • Derek S. Chew, Zhen Li, Benjamin A. Steinberg, Emily O'Brien, Jessica Pritchard, T. Jared Bunch, Daniel B. Mark, Manesh R. Patel, Yelena Nabutovsky, Melissa A. Greiner, Jonathan P. Piccini
| Articolo seguente Articolo seguente
  • Bimodal distribution of atrial fibrillation burden in 3 distinct cohorts: What is ‘paroxysmal’ atrial fibrillation?
  • Benjamin A. Steinberg, Zhen Li, Peter Shrader, Derek S. Chew, T. Jared Bunch, Daniel B. Mark, Yelena Nabutovsky, Rashmee U. Shah, Melissa A. Greiner, Jonathan P. Piccini

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.